Cabaletta Bio, Inc. (CABA)
| Chiusura precedente | 11,50 |
| Aperto | 11,55 |
| Denaro | 11,00 x 800 |
| Lettera | 12,35 x 1000 |
| Min-Max giorno | 11,27 - 12,64 |
| Intervallo di 52 settimane | 7,00 - 16,38 |
| Volume | 164.556 |
| Media Volume | 169.452 |
| Capitalizzazione | 309,163M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,62 |
| Prossima data utili | 08 nov 2021 - 12 nov 2021 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 22,60 |
- GlobeNewswire
Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. “We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will comp
- GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September: Morgan Stanley 19th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fire
- GlobeNewswire
Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV
– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort – – DSG3-CAART persistence observed in all three patients in the second dose cohort during the 28 days following infusion – – Dosing initiated in third cohort at 500 million cells, with biologic activity data from the first two dosing cohorts and third cohort safety data anticipated in 4Q21 – PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabalett
